Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients

European Journal of Ophthalmology

Volumn 25, Issue 4, 2015, Pages 328-332

  Blaslov, Kristina ^a   Bulum, Tomislav ^a   Duvnjak, Lea ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Diabetic retinopathy; Dipeptidyl peptidase 4; Type 1 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV; GLYCOSYLATED HEMOGLOBIN; INSULIN; DPP4 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PREVALENCE; PRIORITY JOURNAL; BLOOD; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; BLOOD GLUCOSE; COLORIMETRY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DIPEPTIDYL PEPTIDASE 4; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84936866190     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000547     Document Type: Article

References (30)

1. Nguyen TT, Kawasaki R, Wang JJ, et al. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care. 2009;32:2075-80.
2. Cuypers MH, Kasanardjo JS, Polak BC. Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. Graefes Arch Clin Exp Ophthalmol. 2000;238:935-41.
3. Fong DS, Aiello L, Gardner TW, et al; American Diabetes Association. Retinopathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S84-7.
4. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-36.
5. LeCaire TJ, Palta M, Klein R, Klein BE, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 2013;36:631-7.
6. Aiello LP; DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:17-23.
7. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26:77-82.
8. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care. 2011;34(Suppl 2):S285-90.
9. Hoffman RP, Dye AS, Huang H, Bauer JA. Effects of glucose control and variability on endothelial function and repair in adolescents with type 1 diabetes. ISRN Endocrinol. 2013;2013:876547.
10. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 2007;30:1305-13.
11. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia. 2006;49:3075-84.
12. Varga T, Firneisz G, Nagy G, Somogyi A. Elevated serum dipeptidyl peptidase-4 activity in type 1 diabetes mellitus: a direct comparison [in Hungarian]. Orv Hetil. 2010;151:899-902.
13. Varga T, Somogyi A, Barna G, et al. Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. Pathol Oncol Res. 2011;17:925-30.
14. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187-215.
15. Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Löffler A, Pfützner A, Forst T. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus: results from an exploratory study. Cardiovasc Diabetol. 2013;8:59.
16. Ott C, Raff U, Schmidt S, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13:19.
17. von Websky K, Reichetzeder C, Hocher B. Linagliptin as addon therapy to insulin for patients with type 2 diabetes. Vasc Health Risk Manag. 2013;9:681-94.
18. Bhatt MP, Lim YC, Ha KS. C-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy. Cardiovasc Res. 2014;104:234-44.
19. Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between adiponectin level, insulin sensitivity, and metabolic syndrome in type 1 diabetic patients. Int J Endocrinol. 2013;2013: 535906.
20. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjølie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia. 1995;38:437-44.
21. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34:2072-7.
22. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol. 2006;26:257-66.
23. Fadini GP, Sartore S, Baesso I, et al. Endothelial progenitor cells and the diabetic paradox. Diabetes Care. 2006;29:714-6.
24. Brunner S, Schernthaner GH, Satler M, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci. 2009;50:392-8.
25. Fonseca VA. New developments in diabetes management: medications of the 21st century. Clin Ther. 2014;1;36:477-84.
26. Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res. 2005;37(Suppl 1):39-43.
27. Shah Z, Pineda C, Kampfrath T, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol. 2011;55:2-9.
28. Trucker ME. Liraglutide benefits patients with type 1 diabetes. Medscape. 2014;May 26.
29. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340:248-55.
30. Forst T, Weber MM, Pfützner A. Cardiovascular benefits of GLP- 1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res. 2012;2012:635472.